ClinicalTrials.gg
Not yet recruitingNCT07941713RestriMIS2Updated Nov 17, 2026

Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children

An observational study in Surgical Approach, Child and Oesophageal Atresia, sponsored by University Hospital, Angers. Not yet recruiting at 11 sites in France. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Angers · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
360
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Esophageal Atresia with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Esophageal Atresia · France.

Started
2026
the only one that year
Observational
7 of 11
4 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
University Hospital, Angers

Among the 11 studies in Esophageal Atresia with a site in France, this one is the only one that started in 2026, is one of 7 observational ones, and was the 11th registered.

Esophageal Atresia

37 studies on the registry are indexed under Esophageal Atresia; 12 are open to participants now.

Browse Esophageal Atresia studies →

Open to participants now

5 of the 11 studies in Esophageal Atresia with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Esophageal Atresia studies recruiting now, 2 (20%) set no upper age limit and 8 (80%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 6 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Esophageal Atresia with a site in France, or all of them as a file.
02

Study summary

Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.

This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.

Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.

A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.

03

Conditions studied

  • Surgical Approach
  • Child
  • Oesophageal Atresia
  • Restrictive Lung Disease
  • Chest Wall Anormality

Browse trials for

Keywords

  • restrictive lung syndrome
  • type 3 esophagial atresia
  • child
  • quality of life
  • convential or mini-invasive surgery
04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).

Eligibility criteria

For thoracoscopy group:

Inclusion Criteria:

  • Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Conversion from thoracoscopy to thoracotomy during the procedure
  • Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
  • For Thoracotomy group*:

Inclusion Criteria :

--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification

  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
  • Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification

For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.

*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).

**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
360 participants (estimated)
Patient registry
No

Groups and cohorts

  • thoracoscopy group

    minimally invasive surgical approach

  • thoracotomy arm

    conventionnal surgical approach

06

What researchers measure

Primary outcomes

  1. to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).

    Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC \> -1.64 Z-score and FVC \< -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society \& European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022.

    Time frame: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Secondary outcomes

  1. to evaluate the importance of restrictive syndrome

    The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome \[-1.64 \> z-score ≥ -2.5\], moderate \[-2.5 \> z-score ≥ -4.0\], or severe \[-4.0 \> z-score\]).

    Time frame: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)

  2. Looking for other respiratory parameters

    Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC \< -1.64 and FVC \< -1.64 z-score) when present

    Time frame: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation

  3. to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact

    The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10).

    Time frame: until spirometry is completed, within a maximum period of 2 years

  4. rate of postoperative complications and any necessary reoperations

    The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries.

    Time frame: up to 2 years after the multidisciplinary consultation

  5. Respiratory-related quality of life during childhood

    It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10).

    Time frame: up to 2 years after the multidisciplinary consultation

  6. to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used

    The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis).

    Time frame: through study completion, within a maximum of 24 months

  7. to assess the mortality rate

    The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry).

    Time frame: through study completion, an average 7 years

  8. Looking for lung volumes variations

    Lung volume variations will be measured by dynamic respiratory MRI data

    Time frame: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2032, 72 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2, 2026
Primary completionEst.
Dec 2, 2032
CompletionEst.
Dec 2, 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941713
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 2, 2026 (estimated)
Primary completion
Dec 2, 2032 (estimated)
Completion
Dec 2, 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

Francoise SCHMITT, MD
Contact
FrSchmitt@chu-angers.fr
+33 2 41 35 42 90
Josue Rakotonjanahary
Contact
JoRakotonjanahary@chu-angers.fr
+33 2 41 35 57 40

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion